Page last updated: 2024-09-04

abiraterone and cabazitaxel

abiraterone has been researched along with cabazitaxel in 100 studies

Compound Research Comparison

Studies (abiraterone)	Trials (abiraterone)	Recent Studies (post-2010) (abiraterone)	Studies (cabazitaxel)	Trials (cabazitaxel)	Recent Studies (post-2010) (cabazitaxel)
942	97	854	601	79	563

Research

Studies (100)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	80 (80.00)	24.3611
2020's	20 (20.00)	2.80

Authors

Authors	Studies
Pal, SK; Sartor, O	2
Chowdhury, S; Harper, P; Powles, T	1
Flaig, TW; Rove, KO	1
Aljumaily, R; Mathew, P	1
Goetz, D	1
Alhasso, A; Ansari, A; Ansari, J; Glaholm, J; Hussain, SA; Mahmood, R	1
Miller, K	1
Sonpavde, G; Sternberg, CN	1
Petrylak, DP	1
Carmichael, C; Josephson, DY; Pal, SK; Sartor, O; Vasani, D	1
Gelpi, F; Gomella, LG; Kelly, WK	1
Sonpavde, G	1
Corn, PG; Dayyani, F; Gallick, GE; Logothetis, CJ	1
Higano, CS	1
de Bono, JS; Massard, C; Michels, RM; Sartor, O	1
Börgermann, C; Molitor, B	1
Gschwend, JE; Heck, MM; Höppner, M; Horn, T; Retz, M; Thalgott, M	1
Fong, MK; Hare, R; Jarkowski, A	1
Bahl, A; De Bono, J; Mason, M; Payne, H; Troup, J	1
Herchenhorn, D; Maluf, FC; Smaletz, O	1
Gottfried, M; Keizman, D; Maimon, N	1
Albiges, L; Escudier, B; Fizazi, K; Loriot, Y; Massard, C	1
Aapro, MS	1
Lewis, B; Pal, SK; Sartor, O	1
Cersosimo, RJ	1
Birtle, A	1
Culine, S; Ouzaid, I; Pouessel, D; Ravery, V	1
Chang, KS; Ezzell, EE; George, BJ	1
Gennigens, C; Sautois, B	1
Agarwal, N; Bellmunt, J; DiLorenzo, G; Sonpavde, G; Vogelzang, NJ; Zhang, TY	1
Hotte, SJ; Loblaw, DA; Walker-Dilks, C; Winquist, E	1
Kolesar, J; Simondsen, K	1
Kellokumpu-Lehtinen, P; Tammela, T	1
Hartmann, RW; Hu, Q; Yin, L	1
de Morrée, ES; de Wit, R; Mathijssen, RH; Moll, JM; Teubel, W; van Royen, ME; van Soest, RJ; van Weerden, WM; Wiemer, EA	1
Balani, G; Gipson, G; Srinivas, S; Tang, J; Wilson, L; Xiang, P; Yu, D; Zhong, L	1
D'Amico, AV	1
Altavilla, A; Attard, G; Bianchini, D; de Bono, JS; Dearnaley, D; Ferraldeschi, R; Lorente, D; Omlin, AG; Parker, C; Pezaro, CJ	1
Bahl, A	1
Albers, P; Eichenauer, R; Geiges, G; Grimm, MO; König, F; Mickisch, G; Miller, K; Pfister, D; Schwentner, C; Suttmann, H; Zastrow, S	1
Al Nakouzi, N; Albigès, L; Beuzeboc, P; de La Motte Rouge, T; Fizazi, K; Gajda, D; Gleave, M; Gross-Goupil, M; Guillot, A; Le Moulec, S; Loriot, Y; Massard, C; Wang, C	1
Tombal, B	1
Baji, P; Berczi, C; Brodszky, V; Géczi, L; Gulácsi, L; Péntek, M; Rencz, F; Szûcs, M	1
Alcaraz, A; Caffo, O; da Silva, FC; Hammerer, P; Merseburger, AS; Roumeguère, T; Rozet, F	1
Ndibe, C; Sonpavde, G; Wang, CG	1
Berlin, A; Fernández, MI	1
Bianco, V; Fiaschi, AI; Francini, E; Laera, L; Petrioli, R; Ponchietti, R; Roviello, G	1
Antonarakis, ES; Carducci, MA; Chen, Y; Eisenberger, MA; Lu, C; Luo, J; Nakazawa, M; Paller, CJ	1
Antonarakis, ES; Carducci, MA; Chen, Y; Denmeade, SR; Eisenberger, MA; Lu, C; Luber, B; Luo, J; Nadal, R; Nakazawa, M; Paller, CJ; Wang, H	1
Crawford, ED; Higano, CS; Hussain, M; Petrylak, DP; Shore, ND	1
Bergman, AM; Bos, MM; Chitu, D; de Morrée, ES; de Wit, R; Goey, SH; Hamberg, P; Mathijssen, RH; Nieuweboer, AJ; van der Meer, N; van Soest, RJ	1
Bria, E; Caffo, O; Galligioni, E; Maines, F; Tortora, G; Trentin, C; Veccia, A	1
Bíró, K; Géczi, L; Küronya, Z; Németh, H	1
Audenet, F; Basset, V; Branchereau, J; de La Taille, A; Flamand, V; Lebdai, S; Lebret, T; Murez, T; Neuzillet, Y; Ploussard, G	1
Ohlmann, CH	1
Antonarakis, ES; Maughan, BL	1
Bertaglia, V; Buttigliero, C; Di Maio, M; Scagliotti, GV; Tucci, M; Vignani, F	1
Arslan, C	1
Aghai, A; Böttcher, R; Burger, H; de Morrée, ES; de Ridder, CM; de Wit, R; Gibson, AA; Mathijssen, RH; Sparreboom, A; van Soest, RJ; van Weerden, WM; Wiemer, EA	1
Albiges, L; Attard, G; Bianchini, D; de Bono, J; Fizazi, K; Loriot, Y; Massard, C; Mateo, J; Mehra, N; Petrylak, DP; Pezaro, C; Ryan, CJ; Shen, L; Varga, A	1
Gallagher, M; Reinhart, M; Sartor, O; Summers, N; Vanderpuye-Orgle, J	1
Bianchini, D; de Bono, J; Gilman, A; Hall, E; IJzerman, M; Kolinsky, M; Lorente, D; Mateo, J; Mehra, N; Miranda, M; Omlin, A; Payne, H; Perez, R; Pezaro, C; Porta, N; Ravi, P; Rescigno, P; Terstappen, L; Tunariu, N	1
Cheng, WY; Dhawan, R; Duh, MS; Gauthier-Loiselle, M; Miao, R; Oh, WK; Sung, J; Vekeman, F	1
Bando, Y; Fujisawa, M; Furukawa, J; Harada, KI; Hinata, N; Nakano, Y; Terakawa, T	1
Bansal, S; Emmenegger, U; Kulkarni, GS; Nam, RK; Saskin, R; Satkunasivam, R; Wallis, CJD	1
Heidenreich, A; Nilsson, S; Parker, C; Shore, N	1
Alexander, DD; Deuson, R; Fryzek, JP; Reichert, H; Summers, N; Townes, L; Vanderpuye-Orgle, J	1
Baldauf, S; Bartsch, G; Borgmann, H; Brandt, MP; Dotzauer, R; Frees, S; Haferkamp, A; Jäger, W; Neisius, A; Schneider, M; Thomas, C; Tsaur, I	1
Cheng, WY; Drea, E; Duh, MS; Gauthier-Loiselle, M; Miao, R; Oh, WK; Szatrowski, TP; Vekeman, F	1
Bolognini, C; Gassian, N; Klajer, E; Loriot, Y; Meynard, G; Thiery-Vuillemin, A	1
Eto, M; Imada, K; Inokuchi, J; Kashiwagi, E; Murakami, T; Shiota, M; Takeuchi, A; Tatsugami, K	1
Buonerba, C; Di Lorenzo, G; Fizazi, K; Pagliuca, M	1
Feng, FY; Fizazi, K; Vicier, C	1
Boegemann, M; Kessel, K; Rahbar, K; Schäfers, M; Schlack, K; Seifert, R; Weckesser, M	1
Bamias, A; Carles, J; Castellano, D; de Bono, J; de Wit, R; Eymard, JC; Feyerabend, S; Fizazi, K; Geffriaud-Ricouard, C; Helissey, C; Iacovelli, R; Kramer, G; Melichar, B; Ozatilgan, A; Sternberg, CN; Sverrisdóttir, Á; Theodore, C; Tombal, B; Wülfing, C	1
Balestra, A; Droz-Perroteau, C; Fizazi, K; Fourrier-Reglat, A; Guiard, E; Joly, F; Jove, J; Lacueille, C; Lamarque, S; Moore, N; Oudard, S; Rouyer, M; Tubach, F	1
Bergh, A; Brattsand, M; Josefsson, A; Lundholm, M; Thellenberg-Karlsson, C; Thysell, E; Widmark, A; Wikström, P; Ylitalo, EB	1
Badrising, SK; Beeker, A; Bergman, AM; Celik, F; Coenen, JLLM; Haanen, JB; Hamberg, P; Lam, MGEH; Loosveld, OJL; Louhanepessy, RD; Oostdijk, A; van der Noort, V; Vegt, E; Wagenaar, N; Zuetenhorst, H; Zwart, W	1
Antonarakis, ES; Eisenberger, MA	1
Taneja, SS	1
Rubio-Briones, J	1
George, DJ; Higano, CS; Jiao, X; Kalinovský, J; Miller, K; Saad, F; Sartor, O; Sternberg, CN; Tangirala, K; Tombal, B	1
Egawa, S; Mori, K; Shariat, SF	1
Di Nunno, V; Massari, F; Mollica, V	1
Abou Chakra, M; Dellis, A; Moussa, M; Papatsoris, A; Sryropoulou, D	1
Ahmed, ME; Alamiri, J; Alom, M; Andrews, JR; Haloi, R; Higa, J; Jeffrey Karnes, R; Joshi, V; Kwon, E; Motterle, G; Shah, PH	1
Bensfia, S; Carles, J; Castellano, D; de Bono, J; de Wit, R; Eymard, JC; Facchini, G; Feyerabend, S; Fizazi, K; Geffriaud-Ricouard, C; Helissey, C; Iacovelli, R; Kramer, G; Liontos, M; Melichar, B; Oudard, S; Ozatilgan, A; Poole, EM; Sternberg, CN; Sverrisdóttir, Á; Theodore, C; Tombal, B; Wülfing, C	1
Iwamoto, H; Izumi, K; Kadomoto, S; Kadono, Y; Kano, H; Makino, T; Mizokami, A; Naito, R; Shigehara, K; Shimada, T; Yaegashi, H	1
Li, Q; Xie, D; Zhang, PF	1
Abouassaly, R; Bryk, DJ; Ericson, K; Fascelli, M; Haywood, SC; Khanna, A; Murthy, PB; O'Connor, LP; Yerram, NK	1
Castellano, D; de Bono, J; de Wit, R; Fizazi, K; Foster, MC; Geffriaud-Ricouard, C; Ozatilgan, A; Sternberg, CN; Suzuki, H; Tombal, B; Wülfing, C	1
Aben, KKH; Bergman, AM; Coenen, JLLM; de Wit, R; Gerritsen, WR; Kuppen, MCP; Mehra, N; Somford, DM; Uyl-de Groot, CA; van den Bergh, ACM; van den Eertwegh, AJM; van Moorselaar, RJA; van Oort, IM; Westgeest, HM	1
Annala, M; Azad, AA; Bacon, JVW; Beja, K; Chi, KN; Ferrario, C; Fu, S; Gingerich, JR; Hotte, SJ; Iqbal, N; Kallio, HML; Khalaf, DJ; Lo, G; North, SA; Nykter, M; Ong, M; Pezaro, CJ; Ruether, JD; Schönlau, E; Sipola, J; Sridhar, SS; Taavitsainen, S; Tran, B; Vandekerkhove, G; Wadhwa, D; Wong, A; Wood, LA; Wyatt, AW	1
Buck, SAJ; de Wit, R; Robbrecht, DGJ	1
Bamias, A; Carles, J; Castellano, D; de Bono, J; de Wit, R; Eymard, JC; Feyerabend, S; Fizazi, K; Geffriaud-Ricouard, C; Helissey, C; Iacovelli, R; Kramer, G; Melichar, B; Ozatilgan, A; Poole, EM; Sternberg, CN; Sverrisdóttir, Á; Theodore, C; Tombal, B; Wülfing, C	1
Bamias, A; Carles, J; Castellano, D; de Bono, J; de Wit, R; Eymard, JC; Feyerabend, S; Fizazi, K; Foster, MC; Geffriaud-Ricouard, C; Helissey, C; Iacovelli, R; Kramer, G; Melichar, B; Ozatilgan, A; Sternberg, CN; Sverrisdóttir, Á; Theodore, C; Tombal, B; Wülfing, C	1
Berlin, D; Chin, JLK; Fernandes, R; Finelli, A; Fleshner, NE; Hamilton, RJ; Hansen, AR; Herrera-Caceres, JO; Hersey, K; Joshua, AM; Kenk, M; Kulkarni, GS; Lajkosz, K; Moussa, M; Sayyid, RK; Sridhar, S; Sweet, J; van der Kwast, T; Veloso, R; Winquist, E; Zlotta, AR	1

Reviews

40 review(s) available for abiraterone and cabazitaxel

Article	Year
A renaissance in the medical treatment of advanced prostate cancer. Oncology (Williston Park, N.Y.), 2010, Volume: 24, Issue:14 Topics: Androstenes; Androstenols; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Denosumab; Humans; Immunotherapy; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; RANK Ligand; Taxoids; Tissue Extracts	2010
New options for the management of castration-resistant prostate cancer: a case perspective. Journal of the National Comprehensive Cancer Network : JNCCN, 2011, Volume: 9 Suppl 3 Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Humans; Immunotherapy; Male; Prostatectomy; Prostatic Neoplasms; Taxoids; Tissue Extracts; Treatment Outcome	2011
Role of second-line systemic treatment post-docetaxel in metastatic castrate resistant prostate cancer- current strategies and future directions. Anti-cancer agents in medicinal chemistry, 2011, Volume: 11, Issue:3 Topics: Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Disease Progression; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Forecasting; Humans; Male; Mitoxantrone; Neoplasm Metastasis; Prednisolone; Prostatic Neoplasms; Quality of Life; Taxoids; Treatment Failure	2011
[Castration resistant prostate cancer 2011]. Aktuelle Urologie, 2011, Volume: 42, Issue:2 Topics: Androgen Antagonists; Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bone Neoplasms; Cancer Vaccines; Clinical Trials as Topic; Docetaxel; Drug Resistance, Neoplasm; Humans; Ketoconazole; Male; Neoplasms, Hormone-Dependent; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Steroid 17-alpha-Hydroxylase; Taxoids; Tissue Extracts	2011
Contemporary management of metastatic castration-resistant prostate cancer. Current opinion in urology, 2011, Volume: 21, Issue:3 Topics: Androstenes; Androstenols; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Castration; Denosumab; Drug Therapy; Humans; Male; Prostatic Neoplasms; RANK Ligand; Taxoids; Testicular Neoplasms; Tissue Extracts	2011
Current clinical trials in castrate-resistant prostate cancer. Current urology reports, 2011, Volume: 12, Issue:3 Topics: Androstenes; Androstenols; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Drug Delivery Systems; Drug Resistance, Neoplasm; Humans; Male; Neoplasm Staging; Neovascularization, Pathologic; Nitriles; Phenylthiohydantoin; Prednisone; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Tissue Extracts; Treatment Outcome	2011
New treatment options for castrate-resistant prostate cancer: a urology perspective. The Canadian journal of urology, 2011, Volume: 18, Issue:4 Topics: Androstenes; Androstenols; Antineoplastic Agents; Chemotherapy, Adjuvant; Docetaxel; Humans; Male; Orchiectomy; Prostatic Neoplasms; Taxoids; Tissue Extracts	2011
Novel therapies for metastatic castrate-resistant prostate cancer. Journal of the National Cancer Institute, 2011, Nov-16, Volume: 103, Issue:22 Topics: Androstenes; Androstenols; Angiogenesis Inhibitors; Anilides; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Atrasentan; Benzamides; Bevacizumab; Biomarkers, Tumor; Bone Remodeling; Cancer Vaccines; Clinical Trials as Topic; Clusterin; Dasatinib; Denosumab; Endothelin-1; Humans; Immunotherapy; Indoles; Ipilimumab; Male; Mice; Mice, SCID; Molecular Targeted Therapy; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms; Pyridines; Pyrimidines; Pyrroles; Pyrrolidines; RANK Ligand; Receptor Cross-Talk; Receptors, Androgen; Signal Transduction; Sunitinib; Taxoids; Thiazoles; Tissue Extracts; Treatment Failure; Tumor Microenvironment; Xenograft Model Antitumor Assays	2011
Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting. The oncologist, 2011, Volume: 16, Issue:11 Topics: Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Docetaxel; Humans; Male; Neoplasm Metastasis; Prednisolone; Prostatic Neoplasms; Radioisotopes; Taxoids; Tissue Extracts	2011
[Second line therapy for castration-resistant prostate cancer (CRPC)]. Der Urologe. Ausg. A, 2012, Volume: 51, Issue:3 Topics: Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Clinical Trials as Topic; Combined Modality Therapy; Docetaxel; Humans; Male; Mitoxantrone; Neoplasm Recurrence, Local; Orchiectomy; Prostatic Neoplasms; Receptors, Androgen; Signal Transduction; Survival Rate; Taxoids; Tissue Extracts	2012
A new era for castrate resistant prostate cancer: a treatment review and update. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2012, Volume: 18, Issue:3 Topics: Androstenes; Androstenols; Animals; Antineoplastic Agents; Drug Approval; Humans; Male; Molecular Targeted Therapy; Orchiectomy; Prostatic Neoplasms; Survival Rate; Taxoids; Tissue Extracts; United States; United States Food and Drug Administration	2012
Castration-resistant prostate cancer: systemic therapy in 2012. Clinics (Sao Paulo, Brazil), 2012, Volume: 67, Issue:4 Topics: Androgen Antagonists; Androstenes; Androstenols; Antineoplastic Agents; Clinical Trials as Topic; Disease Progression; Docetaxel; Evidence-Based Medicine; Humans; Male; Orchiectomy; Prostatic Neoplasms; Taxoids; Tissue Extracts	2012
Metastatic hormone refractory prostate cancer: recent advances in standard treatment paradigm, and future directions. American journal of clinical oncology, 2014, Volume: 37, Issue:3 Topics: Androgen Antagonists; Androstenes; Androstenols; Angiogenesis Inhibitors; Antineoplastic Agents; Cancer Vaccines; Cathepsin K; Dendritic Cells; Docetaxel; Humans; Male; Molecular Targeted Therapy; Prostatic Neoplasms; Radiopharmaceuticals; RANK Ligand; Receptors, Endothelin; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; src-Family Kinases; Taxoids; Tissue Extracts	2014
Management of advanced prostate cancer in senior adults: the new landscape. The oncologist, 2012, Volume: 17 Suppl 1 Topics: Aged; Androgen Antagonists; Androstenes; Androstenols; Antineoplastic Agents; Castration; Clinical Trials as Topic; Disease Management; Docetaxel; Drug Resistance, Neoplasm; Humans; Life Expectancy; Male; Prostate; Prostatic Neoplasms; Taxoids; Treatment Outcome	2012
Management of docetaxel failures in metastatic castrate-resistant prostate cancer. The Urologic clinics of North America, 2012, Volume: 39, Issue:4 Topics: Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Docetaxel; Humans; Male; Neoplasms, Hormone-Dependent; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Radium; Receptors, Androgen; Steroid 17-alpha-Hydroxylase; Taxoids; Treatment Failure	2012
New agents for the management of castration-resistant prostate cancer. The Annals of pharmacotherapy, 2012, Volume: 46, Issue:11 Topics: Androstenes; Androstenols; Antineoplastic Agents; Castration; Humans; Male; Prostatic Neoplasms; Taxoids; Tissue Extracts	2012
Maximizing survival in metastatic castrate-resistant prostate cancer: a clinical viewpoint. Expert review of anticancer therapy, 2013, Volume: 13, Issue:1 Topics: Androstenes; Androstenols; Antineoplastic Agents; Docetaxel; Humans; Male; Neoplasm Metastasis; Orchiectomy; Prognosis; Prostatic Neoplasms; Survival Rate; Taxoids	2013
[Novel agents for the therapy of castration-resistant prostate cancer: overview of pivotal studies and new strategies to come]. Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2013, Volume: 23, Issue:1 Topics: Androstenes; Androstenols; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Denosumab; Disease-Free Survival; France; Humans; Male; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms; Radioisotopes; Radium; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Tissue Extracts; Treatment Outcome	2013
New agents in the arsenal to fight castrate-resistant prostate cancer. Current oncology reports, 2013, Volume: 15, Issue:3 Topics: Androgen Antagonists; Androstenes; Androstenols; Benzamides; Cancer Vaccines; Combined Modality Therapy; Humans; Male; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids; Tissue Extracts; United States	2013
Systemic therapy in men with metastatic castration-resistant prostate cancer: a systematic review. Clinical oncology (Royal College of Radiologists (Great Britain)), 2013, Volume: 25, Issue:7 Topics: Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Taxoids; Tissue Extracts	2013
New treatment options for castration-resistant prostate cancer. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2013, May-15, Volume: 70, Issue:10 Topics: Androstenes; Androstenols; Antineoplastic Agents; Cancer Vaccines; Clinical Trials as Topic; Fees, Pharmaceutical; Humans; Male; Orchiectomy; Prostatic Neoplasms; Taxoids; Tissue Extracts	2013
[Novel drugs provide better therapy for prostate cancer]. Duodecim; laaketieteellinen aikakauskirja, 2013, Volume: 129, Issue:9 Topics: Androstenes; Androstenols; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Denosumab; Gonadotropin-Releasing Hormone; Humans; Male; Nitriles; Oligopeptides; Phenylthiohydantoin; Prostatic Neoplasms; Radioisotopes; Radium; Taxoids	2013
Recent progress in pharmaceutical therapies for castration-resistant prostate cancer. International journal of molecular sciences, 2013, Jul-04, Volume: 14, Issue:7 Topics: Androstenes; Androstenols; Antibodies, Monoclonal, Humanized; Benzamides; Castration; Clinical Trials as Topic; Denosumab; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Taxoids; Tissue Extracts	2013
Metastatic castration-resistant prostate cancer. Part 1: the challenges of the disease and its treatment. European journal of oncology nursing : the official journal of European Oncology Nursing Society, 2013, Volume: 17 Suppl 1 Topics: Alpha Particles; Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Cancer Vaccines; Chlorides; Docetaxel; Humans; Male; Mitoxantrone; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radium; Taxoids; Tissue Extracts	2013
[Metastatic castration-resistant prostate cancer: position paper for structured therapy monitoring]. Der Urologe. Ausg. A, 2014, Volume: 53, Issue:5 Topics: Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Neoplasm Staging; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Taxoids	2014
[Clinical efficacy and safety of enzalutamide in metastatic castration-resistant prostate cancer: systematic review and meta-analysis]. Magyar onkologia, 2014, Volume: 58, Issue:3 Topics: Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Bone Neoplasms; Humans; Male; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome	2014
Androgen deprivation therapy in castrate-resistant prostate cancer: how important is GnRH agonist backbone therapy? World journal of urology, 2015, Volume: 33, Issue:8 Topics: Androstenes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzamides; Gonadotropin-Releasing Hormone; Humans; Leuprolide; Male; Nitriles; Orchiectomy; Phenylthiohydantoin; Practice Guidelines as Topic; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Taxoids; Tissue Extracts	2015
Corticosteroids in the management of prostate cancer: a critical review. Current treatment options in oncology, 2015, Volume: 16, Issue:2 Topics: Adrenal Cortex Hormones; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Mitoxantrone; Palliative Care; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome	2015
[Advances in the treatment of castration-resistant prostate cancer: emphasis in new hormonal therapies]. Revista medica de Chile, 2015, Volume: 143, Issue:2 Topics: Androstenes; Antineoplastic Agents, Hormonal; Benzamides; Biomarkers, Tumor; Disease Progression; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Taxoids	2015
Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies. The Journal of urology, 2015, Volume: 194, Issue:6 Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Benzamides; Disease Progression; Docetaxel; Humans; Male; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Survival Rate; Taxoids; Tissue Extracts	2015
Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer. Critical reviews in oncology/hematology, 2015, Volume: 96, Issue:3 Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease Progression; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate; Taxoids	2015
[Treatment strategies for advanced prostate cancer]. Magyar onkologia, 2015, Volume: 59, Issue:3 Topics: Adrenal Cortex Hormones; Androgen Antagonists; Androstenes; Antineoplastic Agents, Hormonal; Benzamides; Bone Neoplasms; Denosumab; Drug Administration Schedule; Drug Approval; Gonadotropin-Releasing Hormone; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Taxoids; Tissue Extracts	2015
What do we know about treatment sequencing of abiraterone, enzalutamide, and chemotherapy in metastatic castration-resistant prostate cancer? World journal of urology, 2016, Volume: 34, Issue:5 Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Docetaxel; Drug Resistance, Neoplasm; Drug Therapy, Combination; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Taxoids	2016
Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer. Cancer treatment reviews, 2016, Volume: 44 Topics: Androstenes; Anilides; Antineoplastic Agents; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma; Dasatinib; Denosumab; Diphosphonates; Docetaxel; Humans; Imidazoles; Male; Mitoxantrone; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Pyridines; Radioisotopes; Radium; Taxoids; Zoledronic Acid	2016
Efficacy and safety of post-docetaxel therapies in metastatic castration-resistant prostate cancer: a systematic review of the literature. Current medical research and opinion, 2017, Volume: 33, Issue:11 Topics: Androstenes; Benzamides; Compassionate Use Trials; Disease-Free Survival; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome	2017
Current approaches to incorporation of radium-223 in clinical practice. Prostate cancer and prostatic diseases, 2018, Volume: 21, Issue:1 Topics: Androstenes; Benzamides; Bone Neoplasms; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radium; Receptors, Androgen; Taxoids; Treatment Outcome	2018
[DNA damage repair: An emerging strategy in metastatic prostate cancer]. Bulletin du cancer, 2018, Volume: 105, Issue:10 Topics: Androstenes; Antineoplastic Agents; Benzamides; DNA Damage; DNA Repair; Docetaxel; Genomic Instability; Humans; Male; Nitriles; Phenylthiohydantoin; Poly(ADP-ribose) Polymerase Inhibitors; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Taxoids	2018
The Evolving Systemic Treatment Landscape for Patients with Advanced Prostate Cancer. Drugs, 2019, Volume: 79, Issue:4 Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzamides; Clinical Trials as Topic; Docetaxel; Humans; Immunotherapy; Male; Molecular Targeted Therapy; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Radiopharmaceuticals; Radium; Retrospective Studies; Taxoids; Thiohydantoins; Tissue Extracts	2019
Pharmacotherapeutic strategies for castrate-resistant prostate cancer. Expert opinion on pharmacotherapy, 2020, Volume: 21, Issue:12 Topics: Abiraterone Acetate; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Humans; Immunotherapy; Male; Nitriles; Phenylthiohydantoin; Prednisone; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Radium; Taxoids; Tissue Extracts	2020
Contemporary management of advanced prostate cancer: an evolving landscape. Clinical advances in hematology & oncology : H&O, 2021, Volume: 19, Issue:2 Topics: Adenocarcinoma; Androstenes; Benzamides; Clinical Trials as Topic; Combined Modality Therapy; Diagnostic Imaging; Disease Management; Docetaxel; Humans; Male; Multicenter Studies as Topic; Nitriles; Phenylthiohydantoin; Precision Medicine; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radiotherapy, Adjuvant; Radium; Taxoids; Therapies, Investigational	2021

Trials

11 trial(s) available for abiraterone and cabazitaxel

Article	Year
The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer. European journal of cancer (Oxford, England : 1990), 2015, Volume: 51, Issue:17 Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Multivariate Analysis; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Taxoids; Treatment Outcome	2015
Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone. Annals of oncology : official journal of the European Society for Medical Oncology, 2017, 01-01, Volume: 28, Issue:1 Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome	2017
Activity of cabazitaxel in patients with metastatic castration-resistant prostate cancer after treatment with single or dual regimens of novel androgen receptor-targeting agents. Medical oncology (Northwood, London, England), 2017, Aug-17, Volume: 34, Issue:9 Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Docetaxel; Humans; Male; Molecular Targeted Therapy; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Taxoids; Treatment Outcome	2017
Population-based Analysis of Treatment Toxicity Among Men With Castration-resistant Prostate Cancer: A Phase IV Study. Urology, 2018, Volume: 113 Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Canada; Cohort Studies; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Emergency Service, Hospital; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Multivariate Analysis; Nitriles; Ontario; Phenylthiohydantoin; Population Surveillance; Prognosis; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome	2018
Overview of Systemic Therapy Augmenting Management of High-risk Localized Prostate Cancer. European urology focus, 2019, Volume: 5, Issue:2 Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Humans; Male; Prostatic Neoplasms; Radiotherapy; Taxoids; Treatment Outcome; Tubulin Modulators	2019
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. The New England journal of medicine, 2019, 12-26, Volume: 381, Issue:26 Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prednisone; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Taxoids	2019
Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study. The Lancet. Oncology, 2020, Volume: 21, Issue:11 Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Benzamides; Disease-Free Survival; Humans; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Taxoids; Treatment Outcome	2020
Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial. Annals of oncology : official journal of the European Society for Medical Oncology, 2021, Volume: 32, Issue:7 Topics: Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Humans; Male; Nitriles; Phenylthiohydantoin; Prednisone; Prognosis; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome	2021
Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study. European urology, 2021, Volume: 80, Issue:4 Topics: Abiraterone Acetate; Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome	2021
Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study. ESMO open, 2021, Volume: 6, Issue:5 Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Humans; Lymphocytes; Male; Neutrophils; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Taxoids	2021
Neoadjuvant Cabazitaxel plus Abiraterone/Leuprolide Acetate in Patients with High-Risk Prostate Cancer: ACDC-RP Phase II Trial. Clinical cancer research : an official journal of the American Association for Cancer Research, 2023, 10-02, Volume: 29, Issue:19 Topics: Abiraterone Acetate; Humans; Leuprolide; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms	2023

Other Studies

49 other study(ies) available for abiraterone and cabazitaxel

Article	Year
Phase III data for abiraterone in an evolving landscape for castration-resistant prostate cancer. Maturitas, 2011, Volume: 68, Issue:2 Topics: Androstenes; Androstenols; Antineoplastic Agents; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Orchiectomy; Prostatic Neoplasms; Taxoids; Tissue Extracts	2011
Castration refractory prostate cancer: cinderella finally comes to the ball. Onkologie, 2010, Volume: 33, Issue:12 Topics: Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Drug Resistance, Neoplasm; Drugs, Investigational; Humans; Male; Neoplasms, Hormone-Dependent; Orchiectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids; Testosterone; Tissue Extracts	2010
Optimal management of bone metastases in prostate cancer. Current oncology reports, 2011, Volume: 13, Issue:3 Topics: Androstenes; Androstenols; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Neoplasms; Clinical Trials as Topic; Denosumab; Diphosphonates; Humans; Male; Prostatic Neoplasms; RANK Ligand; Taxoids; Tissue Extracts	2011
Current paradigms and evolving concepts in metastatic castration-resistant prostate cancer. Asian journal of andrology, 2011, Volume: 13, Issue:5 Topics: Androstenes; Androstenols; Antineoplastic Agents; Cancer Vaccines; Clinical Trials, Phase III as Topic; Humans; Male; Neoplasm Metastasis; Orchiectomy; Prostatic Neoplasms; Taxoids	2011
Recent advances in the therapy of castration-resistant prostate cancer: the price of progress. Maturitas, 2011, Volume: 70, Issue:2 Topics: Androstenes; Androstenols; Antineoplastic Agents; Clinical Trials, Phase III as Topic; Drug Costs; Humans; Male; Orchiectomy; Prostatic Neoplasms; Taxoids; Tissue Extracts	2011
Abiraterone and increased survival in metastatic prostate cancer. The New England journal of medicine, 2011, 08-25, Volume: 365, Issue:8 Topics: Androgen Antagonists; Androstenes; Androstenols; Antineoplastic Agents; Disease Progression; Disease-Free Survival; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase; Taxoids	2011
New treatment options for patients with metastatic castration-resistant prostate cancer. Cancer treatment reviews, 2012, Volume: 38, Issue:5 Topics: Androstenes; Androstenols; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Denosumab; Diphosphonates; Docetaxel; Humans; Imidazoles; Male; Orchiectomy; Prostatic Neoplasms; Taxoids; Tissue Extracts; Zoledronic Acid	2012
[Compassionate use of abiraterone and cabazitaxel: first experiences in docetaxel-pretreated castration-resistant prostate cancer patients]. Der Urologe. Ausg. A, 2012, Volume: 51, Issue:3 Topics: Aged; Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Compassionate Use Trials; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Orchiectomy; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids	2012
Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities. BJU international, 2012, Volume: 110, Issue:5 Topics: Androgen Antagonists; Androstenes; Androstenols; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Attitude of Health Personnel; Benzamides; Bevacizumab; Forecasting; Humans; Male; Nitriles; Orchiectomy; Phenylthiohydantoin; Practice Patterns, Physicians'; Prostatic Neoplasms; Pyrrolidines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retreatment; Surveys and Questionnaires; Taxoids; Therapies, Investigational; Thionucleotides; Tissue Extracts; Urology	2012
Novel and bone-targeted agents for CRPC. Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23 Suppl 10 Topics: Androgen Antagonists; Androstenes; Androstenols; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Bone Neoplasms; Clinical Trials, Phase III as Topic; Denosumab; Docetaxel; Humans; Ipilimumab; Male; Neoplasms, Hormone-Dependent; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Tissue Extracts; Tumor Microenvironment	2012
New prostate cancer drugs hold promise. Cancer, 2013, Jan-15, Volume: 119, Issue:2 Topics: Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug Approval; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Taxoids; Tissue Extracts; United States	2013
[New treatments for castration-resistant prostate cancer]. Revue medicale de Liege, 2013, Volume: 68, Issue:2 Topics: Androstenes; Androstenols; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials, Phase III as Topic; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Humans; Male; Multicenter Studies as Topic; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome	2013
Management of castrate resistant prostate cancer-recent advances and optimal sequence of treatments. Current urology reports, 2013, Volume: 14, Issue:3 Topics: Androstenes; Androstenols; Anilides; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Humans; Imidazoles; Ipilimumab; Male; Naphthalenes; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Pyridines; Quinolines; Quinolones; Radioisotopes; Radium; Taxoids; Thionucleotides; Tissue Extracts	2013
Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer. European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:18 Topics: Active Transport, Cell Nucleus; Androstenes; Androstenols; Benzamides; Blotting, Western; Cell Line, Tumor; Cell Nucleus; Cell Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance, Neoplasm; Green Fluorescent Proteins; Humans; Male; Microscopy, Confocal; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Taxoids; Time-Lapse Imaging	2013
New therapeutic options in metastatic castration-resistant prostate cancer: Can cost-effectiveness analysis help in treatment decisions? Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2014, Volume: 20, Issue:6 Topics: Androstenes; Antineoplastic Agents; Benzamides; Cost-Benefit Analysis; Decision Trees; Drug Costs; Financing, Personal; Humans; Male; Models, Economic; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Quality-Adjusted Life Years; Survival Rate; Taxoids	2014
US Food and Drug Administration approval of drugs for the treatment of prostate cancer: a new era has begun. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Feb-01, Volume: 32, Issue:4 Topics: Androstenes; Androstenols; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Denosumab; Diphosphonates; Docetaxel; Drug Approval; Drugs, Investigational; Estramustine; Goserelin; Humans; Imidazoles; Male; Mitoxantrone; Nitriles; Oligopeptides; Phenylthiohydantoin; Prostatic Neoplasms; Radioisotopes; Radium; Taxoids; Tissue Extracts; United States; United States Food and Drug Administration; Zoledronic Acid	2014
Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents. European urology, 2014, Volume: 66, Issue:3 Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retreatment; Retrospective Studies; Survival Rate; Taxoids; Treatment Failure	2014
Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies. European urology, 2015, Volume: 68, Issue:2 Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; France; Humans; Kallikreins; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Retrospective Studies; Signal Transduction; Taxoids; Time Factors; Treatment Outcome	2015
Metastatic Castration-resistant Prostate Cancer: Piling Up the Benefits of Chemotherapy. European urology, 2015, Volume: 68, Issue:2 Topics: Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Taxoids	2015
Tolerability of cabazitaxel in patients with metastatic castration-resistant prostate cancer progressing after docetaxel and abiraterone acetate: a single-institution experience. Anti-cancer drugs, 2015, Volume: 26, Issue:8 Topics: Aged; Androstenes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Endpoint Determination; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Failure	2015
Serial blood-based analysis of AR-V7 in men with advanced prostate cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:9 Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Docetaxel; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Nitriles; Phenylthiohydantoin; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Protein Isoforms; Receptors, Androgen; Reverse Transcriptase Polymerase Chain Reaction; Taxoids; Treatment Outcome	2015
Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer. JAMA oncology, 2015, Volume: 1, Issue:5 Topics: Academic Medical Centers; Adenocarcinoma; Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Baltimore; Benzamides; Biomarkers, Tumor; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Genetic Predisposition to Disease; Humans; Kallikreins; Kaplan-Meier Estimate; Male; Middle Aged; Neoplastic Cells, Circulating; Nitriles; Patient Selection; Phenotype; Phenylthiohydantoin; Predictive Value of Tests; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Protein Isoforms; Receptors, Androgen; Risk Factors; RNA, Messenger; Taxoids; Time Factors; Treatment Outcome	2015
[Chemotherapy of prostate cancer]. Der Urologe. Ausg. A, 2015, Volume: 54, Issue:10 Topics: Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Docetaxel; Drug Therapy; Evidence-Based Medicine; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Taxoids; Treatment Outcome	2015
Clinical Relevance of Androgen Receptor Splice Variants in Castration-Resistant Prostate Cancer. Current treatment options in oncology, 2015, Volume: 16, Issue:12 Topics: Androstenes; Androstenols; Benzamides; Bridged-Ring Compounds; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Protein Isoforms; Receptors, Androgen; Taxoids	2015
Singapore Cancer Network (SCAN) Guidelines for the Management of Advanced Castrate-Resistant Prostate Cancer. Annals of the Academy of Medicine, Singapore, 2015, Volume: 44, Issue:10 Topics: Adenocarcinoma; Androgen Antagonists; Androstenes; Antineoplastic Agents; Benzamides; Cancer Vaccines; Docetaxel; Gonadotropin-Releasing Hormone; Humans; Ketoconazole; Male; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Singapore; Taxoids; Tissue Extracts	2015
Do we need new trials for the abiraterone, enzalutamide and cabazitaxel in metastatic castrate-resistant prostate cancer for confirmation of treatment indications? World journal of urology, 2017, Volume: 35, Issue:3 Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Taxoids	2017
Loss of SLCO1B3 drives taxane resistance in prostate cancer. British journal of cancer, 2016, 09-06, Volume: 115, Issue:6 Topics: Adenocarcinoma; Androgens; Androstenes; Animals; Antineoplastic Agents, Phytogenic; Benzamides; Biological Transport; Cell Line, Tumor; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Heterografts; Humans; Male; Mice, Nude; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Nitriles; Organic Anion Transporters, Sodium-Independent; Phenylthiohydantoin; Prostatic Neoplasms; RNA Interference; RNA, Small Interfering; Solute Carrier Organic Anion Transporter Family Member 1B3; Taxoids	2016
Interrogating Metastatic Prostate Cancer Treatment Switch Decisions: A Multi-institutional Survey. European urology focus, 2018, Volume: 4, Issue:2 Topics: Androstenes; Biomarkers, Tumor; Clinical Decision-Making; Disease Progression; Docetaxel; Humans; Male; Neoplasm Metastasis; Neoplastic Cells, Circulating; Practice Patterns, Physicians'; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Surveys and Questionnaires; Taxoids; Treatment Outcome; Tubulin Modulators	2018
Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting. Medical oncology (Northwood, London, England), 2017, Aug-10, Volume: 34, Issue:9 Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Benzamides; Docetaxel; Humans; Longitudinal Studies; Male; Middle Aged; Molecular Targeted Therapy; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Retrospective Studies; Taxoids; Treatment Outcome	2017
Indirect treatment comparison of cabazitaxel for patients with metastatic castrate-resistant prostate cancer who have been previously treated with a docetaxel-containing regimen. PloS one, 2018, Volume: 13, Issue:4 Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Docetaxel; Humans; Male; Meta-Analysis as Topic; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Salvage Therapy; Survival Rate; Taxoids	2018
Docetaxel-rechallenge in castration-resistant prostate cancer: defining clinical factors for successful treatment response and improvement in overall survival. International urology and nephrology, 2018, Volume: 50, Issue:10 Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease-Free Survival; Docetaxel; Follow-Up Studies; Gonadotropin-Releasing Hormone; Humans; Lymphatic Metastasis; Male; Middle Aged; Mitoxantrone; Neoplasm Grading; Orchiectomy; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms, Castration-Resistant; Retreatment; Retrospective Studies; Survival Rate; Taxoids	2018
Real-world outcomes in patients with metastatic castration-resistant prostate cancer receiving second-line chemotherapy versus an alternative androgen receptor-targeted agent (ARTA) following early progression on a first-line ARTA in a US community oncolo Urologic oncology, 2018, Volume: 36, Issue:11 Topics: Aged; Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome	2018
Serum testosterone level as possible predictive marker in androgen receptor axis-targeting agents and taxane chemotherapies for castration-resistant prostate cancer. Urologic oncology, 2019, Volume: 37, Issue:3 Topics: Aged; Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Neoplasm Grading; Nitriles; Phenylthiohydantoin; Progression-Free Survival; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Taxoids; Testosterone	2019
Second line chemotherapy and visceral metastases are associated with poor survival in patients with mCRPC receiving Theranostics, 2019, Volume: 9, Issue:17 Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Taxoids	2019
Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort. British journal of cancer, 2019, Volume: 121, Issue:12 Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Docetaxel; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prednisone; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome	2019
Marked response to cabazitaxel in prostate cancer xenografts expressing androgen receptor variant 7 and reversion of acquired resistance by anti-androgens. The Prostate, 2020, Volume: 80, Issue:2 Topics: Androgen Antagonists; Androstenes; Animals; Antineoplastic Agents; Castration; Cell Line, Tumor; Combined Modality Therapy; Drug Resistance, Neoplasm; Humans; Immunohistochemistry; Male; Mice; Prostatic Neoplasms; Protein Isoforms; Receptors, Androgen; Taxoids; Transcriptome; Xenograft Model Antitumor Assays	2020
A prospective observational registry evaluating clinical outcomes of Radium-223 treatment in a nonstudy population. International journal of cancer, 2020, 08-15, Volume: 147, Issue:4 Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Benzamides; Bone Neoplasms; Chemoradiotherapy; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Nitriles; Outcome Assessment, Health Care; Phenylthiohydantoin; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Radium; Registries; Taxoids	2020
Hormonal Therapy or Chemotherapy for Metastatic Prostate Cancer - Playing the Right CARD. The New England journal of medicine, 2019, 12-26, Volume: 381, Issue:26 Topics: Androstenes; Benzamides; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Taxoids	2019
Re: Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. The Journal of urology, 2020, Volume: 203, Issue:4 Topics: Androstenes; Benzamides; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Taxoids	2020
Re:Cabazitaxel Versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. European urology, 2020, Volume: 77, Issue:4 Topics: Androstenes; Benzamides; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Taxoids	2020
Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States. Clinical genitourinary cancer, 2020, Volume: 18, Issue:4 Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Docetaxel; Follow-Up Studies; Humans; Male; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate; Taxoids; Tissue Extracts	2020
Re: Cabazitaxel Versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. European urology, 2020, Volume: 77, Issue:6 Topics: Androstenes; Benzamides; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Taxoids	2020
Cabazitaxel in Metastatic Prostate Cancer. The New England journal of medicine, 2020, 03-26, Volume: 382, Issue:13 Topics: Androstenes; Benzamides; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Taxoids	2020
Adding carboplatin to chemotherapy regimens for metastatic castrate-resistant prostate cancer in postsecond generation hormone therapy setting: Impact on treatment response and survival outcomes. The Prostate, 2020, Volume: 80, Issue:14 Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carboplatin; Disease Progression; Docetaxel; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Positron Emission Tomography Computed Tomography; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate; Taxoids; Treatment Failure	2020
Androgen receptor signaling-targeted therapy and taxane chemotherapy induce visceral metastasis in castration-resistant prostate cancer. The Prostate, 2021, Volume: 81, Issue:1 Topics: Aged; Aged, 80 and over; Androstenes; Benzamides; Docetaxel; Humans; Incidence; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Retrospective Studies; Risk Factors; Signal Transduction; Taxoids	2021
Cost-effectiveness analysis of cabazitaxel for metastatic castration resistant prostate cancer after docetaxel and androgen-signaling-targeted inhibitor resistance. BMC cancer, 2021, Jan-07, Volume: 21, Issue:1 Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Docetaxel; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Male; Prognosis; Prostatic Neoplasms, Castration-Resistant; Quality-Adjusted Life Years; Survival Rate; Taxoids	2021
Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease. Japanese journal of clinical oncology, 2021, Aug-01, Volume: 51, Issue:8 Topics: Aged; Androstenes; Benzamides; Disease-Free Survival; Humans; Male; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome	2021
The effects of new life-prolonging drugs for metastatic castration-resistant prostate cancer (mCRPC) patients in a real-world population. Prostate cancer and prostatic diseases, 2021, Volume: 24, Issue:3 Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chemoradiotherapy; Docetaxel; Follow-Up Studies; Humans; Male; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Survival Rate; Taxoids	2021
Outcomes of treatment choices in poor prognosis prostate cancer: not against all odds. Annals of oncology : official journal of the European Society for Medical Oncology, 2021, Volume: 32, Issue:7 Topics: Androstenes; Benzamides; Humans; Male; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome	2021